{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-26-000040","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2026-05-13T20:22:33+00:00","discovered_at":"2026-05-13T20:23:31.389750+00:00","generated_at":"2026-05-13T21:48:00.408553+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MacroGenics reports Q1 loss, divests manufacturing, extends cash runway through 2028","bullets":["Manufacturing operations sold to Bora Pharmaceuticals for $122.5M upfront; expected to close Q3 2026.","Expanded ZYNYZ royalty monetization with Sagard: $60M received, up to $20M additional milestone.","Q1 2026 net loss $36.8M ($0.58/share) vs $41.0M loss a year ago; revenue $20.8M (up from $13.2M).","Cash and securities $154.2M at March 31, 2026; with proceeds, cash runway extended through 2028.","Pipeline: Initial MGC026 ADC data expected mid-2026; MGC028 data H2 2026; MGC030 IND planned Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-26-000040","json":"https://secwatch.observer/filing/0001125345-26-000040.json","markdown":"https://secwatch.observer/filing/0001125345-26-000040.md","text":"https://secwatch.observer/filing/0001125345-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/0001125345-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/mgnx-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:48:00.408553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37f5df4f495e7cc534575d7104efd678deaf3426","claim":"MACROGENICS INC reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, MacroGenics, Inc. (the \"Company\") announced financial and operating results as of and for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/0001125345-26-000040-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}